Metsera

Metsera is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases. They are advancing a portfolio of oral and injectable therapies using proprietary peptide engineering platforms like HALO™ and MOMENTUM™. Their unique value proposition lies in their ultra-long-acting peptides and innovative oral delivery systems.


Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $215M

Date: 13-Nov-2024

Investors: Wellington Management, Venrock, Fidelity Management & Research Company, Janus Henderson Investors, T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., Viking Global Investors, Deep Track Capital, RA Capital Management, ARCH Venture Partners, Alpha Wave Ventures, GV, SoftBank Vision Fund 2, Newpath Partners, SymBiosis

Markets: Biotechnology, Pharmaceuticals, Obesity Treatment, Metabolic Disease Treatment

HQ: New York City, New York, United States

Founded: 2022

Website: https://metsera.com

LinkedIn: https://www.linkedin.com/company/metsera/

Twitter: https://x.com/MetseraInc

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/metsera

Pitchbook: https://pitchbook.com/profiles/company/593353-63


Leave a Comment